文献速递神经眼科

Lenadogene Nolparvovec基因治疗Leber遗传性视神经病变189例患者5年安全性分析

Safety of Lenadogene Nolparvovec Gene Therapy Over 5 Years in 189 Patients With Leber Hereditary Optic Neuropathy.
PubMed 文献 · Am J Ophthalmol · 2022-12-08

该汇总分析纳入5项临床研究中189例接受lenadogene nolparvovec单侧或双侧玻璃体内注射的Leber遗传性视神经病变患者,随访至5年。结果显示总体安全性良好,全身耐受性优异,眼部副作用多为轻中度且对常规眼科治疗有反应。

要点

  • 95.2%患者接受9×10¹⁰病毒基因组剂量,87.8%随访至少2年,无不良事件导致研究终止。
  • 眼内炎症见于75.6%治疗眼,多为轻(90.3%)或中度(8.8%),多经局部糖皮质激素 alone 消退。
  • 所有眼压升高均为轻中度,全身治疗相关不良事件仅3例且均非严重。

核心结论

  • Lenadogene nolparvovec总体安全性良好,全身耐受性优异,与有限的生物播散一致。
  • 产品耐受良好,眼部副作用多为轻度且对常规眼科治疗有反应。

研究设计与样本

  • 汇总5项临床研究的安全性数据,共189例患者接受单侧或双侧玻璃体内注射编码人野生型ND4基因的重组腺相关病毒2(rAAV2/2)载体。
  • 不良事件收集贯穿研究全程,随访至5年。
  • 眼内炎症和眼压升高为特别关注的眼部不良事件,其他评估包括眼科检查、载体生物播散和针对rAAV2/2的全身免疫反应。

主要发现

  • 几乎所有患者(95.2%)接受9×10¹⁰病毒基因组,87.8%随访至少2年。
  • 多数患者(75.1%)经历至少1例全身不良事件,但全身治疗相关不良事件仅见于3例患者且均非严重。
  • 眼内炎症见于75.6%的lenadogene nolparvovec治疗眼,几乎均发生在前房(58.8%)或玻璃体(40.3%),强度为轻度(90.3%)或中度(8.8%),多数仅用局部糖皮质激素即消退。
  • 所有眼压升高均为轻中度。
  • 无不良事件导致研究终止,lenadogene nolparvovec的生物播散和全身免疫反应有限,双侧与单侧治疗患者的安全性特征相当。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the safety profile of lenadogene nolparvovec (Lumevoq) in patients with Leber hereditary optic neuropathy. DESIGN: Pooled analysis of safety data from 5 clinical studies. METHODS: A total of 189 patients received single unilateral or bilateral intravitreal injections of a recombinant adeno-associated virus 2 (rAAV2/2) vector encoding the human wild-type ND4 gene. Adverse events (AEs) were collected throughout the studies, up to 5 years. Intraocular inflammation and increased intraocular pressure (IOP) were ocular AEs of special interest. Other assessments included ocular examinations, vector bio-dissemination, and systemic immune responses against rAAV2/2. RESULTS: Almost all patients (95.2%) received 9 × 1010 viral genomes and 87.8% had at least 2 years of follow-up. Most patients (75.1%) experienced at least one systemic AE, but systemic treatment-related AEs occurred in 3 patients; none were serious. Intraocular inflammation was reported in 75.6% of lenadogene nolparvovec-treated eyes. Almost all intraocular inflammations occurred in the anterior chamber (58.8%) or in the vitreous (40.3%), and were of mild (90.3%) or moderate (8.8%) intensity; most resolved with topical corticosteroids alone. All IOP increases were mild to moderate in intensity. No AE led to study discontinuation. Bio-dissemination of lenadogene nolparvovec and systemic immune response were limited. The safety profile was comparable for patients treated bilaterally and unilaterally. CONCLUSIONS: Lenadogene nolparvovec had a good overall safety profile with excellent systemic tolerability, consistent with limited bio-dissemination. The product was well tolerated, with mostly mild ocular side effects responsive to conventional ophthalmologic treatments.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Vignal-Clermont C, Yu-Wai-Man P, Newman NJ, et al. Safety of Lenadogene Nolparvovec Gene Therapy Over 5 Years in 189 Patients With Leber Hereditary Optic Neuropathy. Am J Ophthalmol. 2022. PMID: 36496192. doi:10.1016/j.ajo.2022.11.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。